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A B S T R A C T
Purpose
To explore whether population-related pharmacogenomics contribute to differences in patient
outcomes between clinical trials performed in Japan and the United States, given similar study
designs, eligibility criteria, staging, and treatment regimens.
Methods
We prospectively designed and conducted three phase III trials (Four-Arm Cooperative Study,
LC00-03, and S0003) in advanced-stage, non–small-cell lung cancer, each with a common arm of
paclitaxel plus carboplatin. Genomic DNA was collected from patients in LC00-03 and S0003 who
received paclitaxel (225 mg/m2) and carboplatin (area under the concentration-time curve, 6).
Genotypic variants of CYP3A4, CYP3A5, CYP2C8, NR1I2-206, ABCB1, ERCC1, and ERCC2 were
analyzed by pyrosequencing or by PCR restriction fragment length polymorphism. Results were
assessed by Cox model for survival and by logistic regression for response and toxicity.
Results
Clinical results were similar in the two Japanese trials, and were significantly different from
the US trial, for survival, neutropenia, febrile neutropenia, and anemia. There was a significant
difference between Japanese and US patients in genotypic distribution for CYP3A4*1B (P  .01),
CYP3A5*3C (P  .03), ERCC1 118 (P  .0001), ERCC2 K751Q (P  .001), and CYP2C8 R139K
(P  .01). Genotypic associations were observed between CYP3A4*1B for progression-free
survival (hazard ratio [HR], 0.36; 95% CI, 0.14 to 0.94; P  .04) and ERCC2 K751Q for response
(HR, 0.33; 95% CI, 0.13 to 0.83; P  .02). For grade 4 neutropenia, the HR for ABCB1 3425C3T
was 1.84 (95% CI, 0.77 to 4.48; P  .19).
Conclusion
Differences in allelic distribution for genes involved in paclitaxel disposition or DNA repair were
observed between Japanese and US patients. In an exploratory analysis, genotype-related
associations with patient outcomes were observed for CYP3A4*1B and ERCC2 K751Q. This
common-arm approach facilitates the prospective study of population-related pharmacogenomics
in which ethnic differences in antineoplastic drug disposition are anticipated.
J Clin Oncol 27:3540-3546. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Results may vary between different clinical trials that
evaluate the same treatment regimen for many rea-
sons, including trial design, eligibility criteria, pa-
tient characteristics, and subtle alterations in the
treatment regimens themselves. An additional ex-
planation for divergence of outcomes is host-related
genetic differences associated with ethnicity, which
is particularly pertinent when trials that are per-
formed in different parts of the world are compared.
More than 10 years ago, the Southwest On-
cology Group (SWOG) established a collabora-
tion with Japanese investigators of lung cancer to
provide a forum for exchange of research data, to
facilitate standardization of clinical trial design
and conduct, and to establish areas for joint col-
laboration.1 We hypothesized that outcome differ-
ences between trials performed in Japan and the
United States that evaluated similar treatment regi-
mens in advanced-stage, non–small-cell lung cancer
(NSCLC) could be explained by population-related
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pharmacogenomics. To evaluate this possibility, we prospectively de-
signed three phase III trials, (Four-Arm Cooperative Study [FACS],
LC00-03, and S0003), each with similar patient eligibility criteria,
staging, and treatment with a common arm of paclitaxel plus carbo-
platin. We have reported previously that, despite this effort at trial
standardization, differences in clinical outcomes were observed in
Japanese versus US patients treated on these studies.2,3 Herein, we
report the results of a clinical and pharmacogenomic analysis that
involved patients from two of the three clinical trials (LC00-03 and
S0003), and we report implications for additional studies by using this
clinical research approach in which population-related differences in
drug disposition are anticipated.
METHODS
Patients
The clinical trial methodology employed was prospective design of three
separate-but-equal, randomized, phase III trials in advanced-stage NSCLC,
each with its own comparator regimens but linked by a common treatment
arm of paclitaxel plus carboplatin. In FACS, patients were randomly assigned
to a standard treatment in Japan (irinotecan plus cisplatin) versus experimen-
tal arms of paclitaxel plus carboplatin, gemcitabine plus cisplatin, and vinorel-
bine plus cisplatin. LC00-03 compared paclitaxel plus carboplatin to the
nonplatinum regimen of sequential vinorelbine plus gemcitabine followed by
docetaxel, whereas patients on S0003 were randomly assigned to paclitaxel
plus carboplatin with or without the hypoxic cytotoxin tirapazamine.
Clinical results for the three trials have been previously presented and
published separately.4-6 Common elements of eligibility criteria are sum-
marized here. All patients had histologically or cytologically confirmed
chemotherapy-naïve NSCLC with stage IV (ie, no brain metastases) or selected
stage IIIB disease (ie, positive pleural or pericardial effusion or multiple ipsi-
lateral lung nodules); measurable or assessable disease, performance status
(PS) of 0 or 1; and adequate hematologic, hepatic, and renal function. All
patients gave written informed consent in accordance with institutional regu-
lations, and each protocol was approved by the respective institutional review
boards; trials were conducted with adherence to the Helsinki Declaration.
Treatment Schedule, Dose Modifications, and
Toxicity Assessment
Study elements of S0003, FACS and LC00-03 were designed to be as
similar as possible: each study contained a common arm of paclitaxel plus
carboplatin, which was repeated on a 21-day schedule. In all three studies,
carboplatin was dosed at an area under the concentration-time curve (AUC) of
6.0 mg/mL/min on day 1. Paclitaxel was dosed at 225 mg/m2 in S0003 and
LC00-03 and at 200 mg/m2 in FACS because of regulatory requirements for
this study; in each study, paclitaxel was delivered as a 3-hour infusion on day 1.
Premedication to prevent paclitaxel-related allergic reactions were similar.
Prophylactic granulocyte colony-stimulating factor was not utilized. A com-
plete blood count and chemistries were performed on day 1 of each cycle. Dose
modifications occurred as previously described.4 Patients were evaluated every
two cycles for objective response by using RECIST (Response Evaluation
Criteria in Solid Tumors) criteria7 Toxicity grading was performed in accor-
dance with the National Cancer Institute Common Toxicity Criteria, version
2.0, in each study.8
DNA Extraction and Genotyping
Specimens were not available from FACS; therefore, this analysis com-
pares pharmacogenomic results from LC00-03 with S0003. Whole-blood
specimens were collected from consenting patients at the time of enrollment
on to LC00-03 and S0003. For S0003, DNA was extracted from patient plasma
by using the Gentra PureGene Blood Kit (Gentra, Minneapolis, MN) and the
QIAamp DNA Blood midi kit (Qiagen, Valencia, CA), and DNA was recon-
stituted in a buffer that contained 10 mmol/L Tris (pH 7.6) and 1 mmol/L
EDTA, as previously described.9 For LC00-03, DNA was extracted from buffy
coats by using the GenElute Blood Genomic DNA Kit (Sigma-Aldrich, St
Louis, MO). Selected genotypic variants related to paclitaxel disposition (ie,
the ABC transporter superfamily [multidrug resistance {MDR} transporter 1
P-glycoprotein, ABCB1 3435C3T], the pregnane X receptor (PXR, NR1I2-
206 deletion), CYP3A4 (CYP3A4*1B 392A3G, 5 untranslated region),
CYP3A5 (CYP3A5*3C 6986A3G, splice variant), CYP2C8 (CYP2C8*3
416G3A, R139K) or to platinum-related DNA repair enzymes ERCC1
(118C3T, silent) and ERCC2 (XPD, K751Q) previously reported to be of
functional consequence were analyzed by polymerase chain reaction (PCR) or
pyrosequencing, as previously described.9-13 Briefly, PCR was conducted by
using Amplitaq Gold PCR master mix (ABI, Foster City, CA), 5 pmol of each
primer, and 5 to 10 ng of DNA. Pharmacogenetic analysis was conducted by
using the Pyrosequencing hsAPSQ96 instrument and software (Biotage, Upp-
sala, Sweden). The genotype was considered variant if it differed from the
Reference Sequence consensus sequence for the single-nucleotide polymor-
phism (SNP) position (http://www.ncbi.nlm.nih.gov/RefSeq/). The ERCC1
polymorphism was analyzed by PCR restriction fragment length polymor-
phism, as previously described.14
Statistical Methods
Comparison of clinical results among the three trials was prospectively
planned and was coordinated through the SWOG statistical center. Pharma-
cogenomic results were assessed by Cox model for progression-free survival
(PFS) and overall survival and by logistic regression for response and toxicity,
adjusted for sex and histology.15 Comparisons of patient demographics, tox-
icity, and efficacy parameters were made, when applicable, from the available
data sets, by two-sample t tests, log-rank tests, and Wilcoxon rank sum tests.
RESULTS
Clinical Results Summary
Clinical results are presented for all three trials to document
similarities between the two Japanese trials compared with the US
S003 trial, whereas pharmacogenomic information was derived only
from LC00-03 and S0003. Table 1 summarizes characteristics of pa-
tients on the paclitaxel-plus-carboplatin arms of each of the three
trials. The median ages and age ranges were similar, and there were
no significant differences in sex, stage, or histology. In S0003, 3% of
patients self-reported Asian heritage, not additionally specified. Tox-
icity, efficacy, and dose delivery comparisons are listed in Table 2,
which compares S0003 versus FACS/LC00-03 when applicable.
Grades 3 to 4 neutropenia and febrile neutropenia were comparable










No. % No. % No. %
Age, years .03
Median 63 65 63
Range 33-74 33-81 28-80
Female sex 46 32 61 31 68 37 .42
Disease stage IV 117 81 162 82 161 87 .20
Nonsquamous tumor type 114 79 167 85 152 83 .17
Abbreviation: FACS, four-arm cooperative study.
Two-sample t test to compare LC00-03 and S0003 data. Patient-level data
not available for FACS.
Japan-USA Common-Arm Analysis
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in FACS and LC00-03 and were significantly greater than in S0003.
Anemia was more frequent in FACS compared with the two other
trials (Table 2). Efficacy comparisons are summarized in Table 3.
Response rates were similar between the three trials and ranged from
32% to 36%. Median PFS rates were 4.5, 6, and 4 months in FACS,
LC00-03, and S0003, respectively. Median survival rates were higher in
the Japanese studies at 12 and 14 months, versus 9 months in S0003,
and 1-year survival was significantly higher in FACS and LC00-03 than
in S0003 (P .0004). Dose delivery, summarized in Table 4, was lower
in FACS than in S0003 and LC00-03. Dose reductions were similar
between LC00-03 and S0003. Dose reduction data were not available
from FACS.
Pharmacogenomic Results
Table 5 lists allelic distributions of patients with common, het-
erozygous, and variant alleles in the Japanese (LC00-03) and US
(S0003) trials. Fisher’s exact test was used to determine whether allele
distributions were different between the populations. There were sig-
nificant differences between patients from Japan (LC00-03) and the
United States (S0003) in genotype distribution for CYP3A4*1B
(P  .01), CYP3A5*3C (P  .03), ERCC1 118 (P  .0001), ERCC2
K751Q (P  .001), and CYP2C8*3 (P  .01).
Across populations, genotypic correlations were observed be-
tween CYP3A4*1B for PFS (hazard ratio [HR], 0.36; 95% CI, 0.14 to
0.94; P .04) and ERCC2 K751Q for response (HR, 0.33; 95% CI, 0.13
to 0.83; P  .02). There were no other significant associations noted
(Table 6). For grade 4 neutropenia, the HR for ABCB1 3425C3T was
1.84 (95% CI, 0.77 to 4.48; P  .19). The relationship between the
ERCC2 polymorphism and patient response stems principally from
US patients. All but one Japanese patient was homozygous for the
common allele (A/A). Those who harbored one or more variant alleles
were significantly more likely to respond to treatment compared with
those who had the common genotype. The response rate for patients
with variant alleles was 51% versus 19% for patients homozygous for
the common allele P  .004). However, no differences were observed
in overall survival when stratified by this locus.
In S0003 (ie, the US trial), there were seven African American
patients who had specimens available for genotyping. African Ameri-
can patients accounted for all seven patients who were heterozygous or
homozygous for the CYP3A4*1B allele (Table 5). Additionally, the
three patients with the common allele for CYP3A5*C were Afri-
can American.
DISCUSSION
This report describes the culmination of a unique multinational and
multistudy collaboration that explores the hypothesis that clinical
differences in treatment outcomes between Japanese and US patients
with NSCLC may be explained, in part, by pharmacogenomic factors.
Potential differences in drug disposition related to ethnic variability in
distribution of relevant single nucleotide polymorphisms are well
recognized. To our knowledge, however, the current project repre-
sents the first attempt to prospectively incorporate study of this topic
into a joint clinical trial design. To preplan such a multinational
endeavor required a high level of collaboration and compromise
among all participants, including, in the case of FACS, Japanese regu-
latory authorities. Nevertheless, this report demonstrates the overall
feasibility of using a common-arm methodology to investigate this
research topic, in which a single, prospectively planned, joint study
cannot be conducted. Considering the limitations of the clinical and
pharmacogenomic data sets generated in this effort, and considering
the multiple comparisons generated, the results reported here should
be viewed as exploratory only and as primarily useful for refining this
common-arm model of multinational collaboration. Even so, the
clinical results are remarkably consistent with those anticipated, in
which expectations were for both improved efficacy and higher levels
of toxicity in Japanese patients who received a similar treatment regi-
men. Observation of clinical differences despite reduced paclitaxel




FACS (n  148) LC00-03 (n  197) S0003 (n  184)
No. % No. % No. %
Neutropenia grades 3-4 130 88 137 70 70 38  .0001
Febrile neutropenia grades 3-4 27 18 24 12 4 2  .0001
Thrombocytopenia grades 3-4 16 11 14 7 12 6.5 .31
Anemia grades 3-4 22 15 16 8 12 7 .03
Neuropathy grades 2-4 25 17 32 16 30 16 .99
Abbreviation: FACS, four-arm cooperative study.











No. 47 73 61
% 32 37 33
PFS, months 4.5 6 4 .04
MST, months 12 14 9 .0006
1-year survival 51% 57% 37% .0004
Abbreviations: FACS, four-arm cooperative study; PFS, progression-free
survival; MST, median survival time.
Log-rank test to compare LC00-03 and S0003. Patient-level data not
available for FACS.
Gandara et al
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dosing and drug delivery of paclitaxel plus carboplatin in the FACS
Japanese study highlights the contrast.
The rationale for conducting this common-arm project specifi-
cally in collaboration with Japanese investigators was based on several
factors, including the established SWOG interaction described earlier,
the high quality of lung cancer investigation by Japanese cooperative
groups, and prior literature that suggested that overall, Japanese pa-
tients achieve better results than their US counterparts. However, the
most compelling rationale was prior pharmacogenomic literature,
which suggested that relevant drug disposition differences might exist
between US and Japanese populations treated with cancer chemo-
therapeutic agents. Well recognized here are alterations in irinote-
can metabolism as a result of variability in the allelic distribution of
UDP-glucuronosyltransferases, particularly UGT1A1*28 in different
ethnic groups, as Asians have a much lower frequency of variant
alleles. Recently, a comparative analysis of patient-level data from
phase III trials in small-cell lung cancer in Japan (J9511) and the
United States (S0124) demonstrated significant differences in toxicity
profiles between the two groups. In addition, a pharmacogenomic
analysis of S0124 showed significant associations between genotypic
variants and toxicity levels.16,17
The genes evaluated in this study were selected on the basis of
their potential to influence paclitaxel disposition or DNA damage
repair. Paclitaxel is principally eliminated through multiple hydroxy-
lation reactions mediated by cytochrome isoforms CYP2C8, CYP3A4,
and CYP3A5.18,19 The CYP2C8*3 variant (R139K), which is associ-
ated with decreased metabolism of paclitaxel, occurs at a frequency
of 9% to 15% in white patients but is rare in African and Asian
populations.20-23 In this study, the allele frequency in the US popula-
tion was 12%, which was significantly different from the less-than-1%
frequency in the Japanese cohort (P  .01). CYP2C8 genotypic vari-
ability at R139K was not significantly associated with patient outcome.
CYP3A isozymes account for 45% to 60% of paclitaxel metabolism.24
In white patients, the CYP3A5 allele is commonly nonfunctional as a
result of a transition in intron 3 that produces a truncated splice
variant.25 Our findings are consistent with that of Hustert et al,25 who
reported frequencies of functional CYP3A5 as 5% in white patients,
29% in Japanese patients, and 73% in African American patients. Of
patients enrolled onto the S0003 trial conducted in the US, three of
three with the functional allele (indicated as common in Table 5)
were African Americans, as were three of the seven heterozygous
patients. Although trends were observed, CYP3A5*3C genotypic
variability was not significantly associated with patient outcome
(overall survival P  .07; PFS P  .09), perhaps related to the small
sample size. Similarly, the CYP3A4*1B allele was observed in seven of
seven African American patients but was absent in white and Japanese
patients. In vitro studies suggest that the CYP3A4*1B variant has
enhanced activity over common allele.26 An association was observed
between occurrence of the CYP3A4*1B and PFS (P  .04); however,
this association should be interpreted in the context that only African
American patients harbored this allele. Thus, it remains unclear
whether this potential relationship with outcome is associative or
causative. The PXR (NR1I2-206 deletion) is a master regulator of
genes involved in xenobiotic detoxification and influences transcrip-
tion of CYP3A4, CYP3A5, CYP2C8, and MDR-1 (ABCB1).27-29 Pacli-
taxel can activate PXR, which enhances drug clearance through
increased activity of MDR1.30 No significant differences by genotype
were observed for PXR or ABCB1, although there was a trend toward




FACS (n  145) LC00-03 (n  197) S0003 (n  184)
No. % No. % No. %
Median cycles delivered 3.5 4 4 .07
Received  three cycles 35 24 118 60 100 54  .0001
Received six cycles 16 11 58 29 68 36.5  .0001
Dose was reduced No data No data 100 51 98 26 .63*
Abbreviation: FACS, four-arm cooperative study.
Wilcoxon rank sum test to compare LC00-03 and S0003. Patient-level data not available for FACS.







Japan 73 0 0 .01
United States 64 4 3
CYP3A5C
Japan 7 16 50 .03
United States 3 7 66
CYP2C8 (R139K)
Japan 69 2 0 .01
United States 57 7 5
ABCB1 (3435C3T)
Japan 33 21 17 .11
United States 24 23 29
NR1l2 (206 deletion)
Japan 51 19 5 .25
United States 40 25 8
ERCC1 (118)
Japan 8 27 43  .0001
United States 23 33 19
ERCC2 (K751Q)
Japan 73 1 0  .001
United States 37 27 8
NOTE. LC00-03 is the trial in Japan; S0003 is the trial in the United States.
Fisher’s exact test was used to determine whether allele distributions were
different between the populations.
Abbreviations: Com, common allele; Het, heterozygous allele; Var,
variant allele.
Japan-USA Common-Arm Analysis
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neutropenia (P  .19) for patients who harbored the ABCB1 3435
common allele.
The ERCC2 gene, also known as xeroderma pigmentosum
complementation group D, encodes a DNA helicase which complexes
with TFIIH, a transcription factor essential for replication and nucle-
otide excision repair.31 Several nonsynonymous SNPs have been de-
scribed in this gene, including an Asp3Asn (G3A) at codon 312 in
exon 10 and a Lys3Gln (A3C) at codon 751 in exon 23 and are likely
in linkage disequilibrium with each other.32,33 The functional conse-
quences of these SNPs are still in contention, and the majority of
studies indicate that variants in these alleles result in reduced DNA
repair capacity.34-41 Additionally, most studies indicate that ERCC2
variants confer an increased risk of lung cancer.32,34,35,42-48 In this
study, 51% of patients (ie, 37 of 72 patients) from the US were ho-
mozygous wild type for the common (A) allele. These patients were
significantly less likely to respond to treatment compared with US
patients who had one or more variant alleles (A/C or C/C). How-
ever, no differences in overall survival were observed on the basis of
ERCC2 K751Q allele frequencies. In addition, this allele cannot
account for the improved survival experienced by Japanese pa-
tients, as they uniformly harbored the common A/A genotype (and
only one patient harbored A/C). The ERCC1 118 C3T SNP does
not result in an amino acid substitution, although studies have
nevertheless identified associations with patient outcome in vari-
ous tumor types.49 It has been suggested that this variant may
modulate ERCC1 mRNA and protein expression and/or may be in
linkage disequilibrium with other functional SNPs.14,50,51 How-
ever, three reports in NSCLC found no associations between the
ERCC1 118 and patient outcome.52-54 Here, we found a highly
significant divergence in allele frequency between Japanese and US
patients (P  .0001); however, no impact on patient outcome
was observed.
In summary, the results of cancer clinical trials to test the same
regimen may differ for a variety of reasons, including differences
related to ethnicity. FACS, LC00-03, and S0003 were prospectively
designed to facilitate a comparison of patient outcomes and phar-
macogenomic results, in a setting where joint clinical trials spon-
sored by the US National Cancer Institute were not possible. Our




Comparison HR 95% CI P
ABCB1 3425
Overall survival Com v Het/Var (CC v CT/TT) 1.09 0.71 to 1.67 .69
PFS 1.04 0.70 to 1.56 .82
Response 0.97 0.39 to 2.38 1.00
Neutropenia 0.54 0.22 to 1.30 .19
CYP2C8 R139K
Overall survival Com v Het/Var (GG v GA/AA) 1.09 0.61 to 1.96 .76
PFS 1.12 0.63 to 2.00 .69
Response 1.92 0.46 to 11.11 .51
Neutropenia 1.30 0.35 to 5.00 .87
CYP3A41B
Overall survival Com v Het/Var (AA v AG/GG) 0.74 0.32 to 1.72 .48
PFS 0.36 0.14 to 0.94 .04
Response 0.63 0.10 to 4.76 .84
Neutropenia 0.44 0.04 to 2.94 .58
CYP3A53C
Overall survival Com/Het v Var (AA/AG v GG) 1.64 0.95 to 2.86 .07
PFS 1.56 0.93 to 2.63 .09
Response 1.61 0.53 to 4.76 .47
Neutropenia 1.30 0.44 to 3.85 .78
ERCC1 (118)
Overall survival TT v TC/CC 1.20 0.74 to 1.96 .45
PFS 1.11 0.69 to 1.82 .65
Response 1.45 0.48 to 4.17 .61
Neutropenia 0.57 0.20 to 1.61 .35
ERCC2 K751Q
Overall survival Com v Het/Var (AA v AC/CC) 0.97 0.63 to 1.49 .89
PFS 0.85 0.55 to 1.30 .45
Response 0.33 0.13 to 0.83 .02
Neutropenia 0.75 0.30 to 1.85 .63
nr1I2-206 del
Overall survival Com v Het/Var 206 deletion 0.82 0.53 to 1.25 .35
PFS 0.93 0.63 to 1.39 .75
Response 0.82 0.34 to 2.00 .77
Neutropenia 0.88 0.37 to 2.08 .90
Abbreviations: HR, hazard ratio; PFS, progression-free survival; Com, common allele; Het, heterozygous allele; Var, variant allele.
Gandara et al
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results suggest that global clinical trials (ie, those conducted inter-
nationally) should be carefully designed and conducted to account for
potential genetic differences in the patient populations studied. This
common-arm approach provides a model for the prospective study of
population-related pharmacogenomics in which ethnic differences in
antineoplastic drug disposition are anticipated.
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